Medicine Information

Vilatide

Name: Vilatide
Brand: Vilatide
Rating: 4.5 (117 reviews)

Inhalation Capsule25 mcgBronchodilator (Long-acting Beta2-adrenergic Agonist)ATC: R03AC12

Generic Name

vilatide-25-mcg-inhalation-capsule

Manufacturer

PharmaCorp Inc.

Country

USA

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
vilatide 25 mcg inhalation capsule	৳ 25.00	৳ 250.00

Description

Overview of the medicine

Vilatide 25 mcg Inhalation Capsule is a long-acting beta2-adrenergic agonist (LABA) used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma. It helps to relax the muscles in the airways, improving breathing.

Uses & Indications

Maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Maintenance treatment of asthma in patients 12 years of age and older (in combination with an inhaled corticosteroid, not as monotherapy).

Dosage

Adults

The recommended dosage is 25 mcg inhaled once daily, at the same time each day. Do not use more than once every 24 hours.

Elderly

No dosage adjustment is required for elderly patients.

Renal_impairment

No dosage adjustment is required for patients with renal impairment.

How to Take

Vilatide inhalation capsules are for oral inhalation only and should be administered using the provided inhaler device. Do not swallow the capsules. Follow the instructions for use provided with the inhaler.

Mechanism of Action

Vilatide acts selectively on beta2-adrenergic receptors found in the smooth muscles of the airways, leading to bronchodilation. It stimulates intracellular adenyl cyclase, which catalyzes the conversion of ATP to cyclic-3', 5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels relax bronchial smooth muscle and inhibit the release of mediators from mast cells in the airway.

Pharmacokinetics

Onset

Bronchodilation typically occurs within 5-10 minutes after a single dose.

Excretion

Excreted primarily via feces (approximately 70%) and urine (approximately 30%).

Half life

The effective half-life is approximately 20-25 hours, allowing for once-daily dosing.

Absorption

Rapid systemic absorption occurs from the lungs after oral inhalation. Peak plasma concentration is typically reached within 5-15 minutes.

Metabolism

Primarily metabolized in the liver via the CYP3A4 enzyme.

Side Effects

Contraindications

Hypersensitivity to Vilatide or any component of the formulation.
Not indicated for the primary treatment of acute episodes of bronchospasm (i.e., rescue therapy) or for acute deteriorations of COPD or asthma.

Drug Interactions

Beta-blockers

May blunt the pulmonary effect of beta-agonists like Vilatide. Non-cardioselective beta-blockers should generally be avoided. If necessary, cardioselective beta-blockers should be used with caution.

Diuretics (e.g., Thiazide or Loop Diuretics)

ECG changes and/or hypokalemia, which may result from the administration of non-potassium-sparing diuretics, can be acutely worsened by beta-agonists. Use with caution.

Strong CYP3A4 Inhibitors (e.g., Ketoconazole, Ritonavir)

Concomitant use may increase systemic exposure to Vilatide, potentially leading to increased cardiovascular adverse effects. Use with caution or avoid.

Storage

Store below 30°C in a dry place. Protect from light and moisture. Keep out of reach of children. Do not refrigerate or freeze.

Overdose

Symptoms of overdose include excessive beta-adrenergic stimulation, such as tachycardia, palpitations, tremor, headache, and nervousness. Treatment should be supportive and symptomatic. Consider cardiovascular monitoring in severe cases.

Pregnancy & Lactation

Pregnancy Category C. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Caution should be exercised when administered to a nursing mother. Consult a healthcare professional before use during pregnancy or lactation.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

30 capsules per pack60 capsules per pack

Shelf Life

24 months from the date of manufacture when stored as recommended.

Availability

Available in pharmacies

Approval Status

Approved by regulatory authorities

Patent Status

Active patent for formulation/delivery

Clinical Trials

Vilatide has undergone extensive Phase III clinical trials demonstrating its efficacy and safety in patients with COPD and asthma. Studies have shown significant improvements in FEV1 and reductions in exacerbation rates.

Lab Monitoring

Routine pulmonary function tests (e.g., FEV1)
Monitoring for hypokalemia and hyperglycemia (especially in susceptible patients).

Doctor Notes

Educate patients thoroughly on correct inhaler technique to ensure optimal drug delivery and efficacy.
For asthma patients, Vilatide should always be prescribed with an inhaled corticosteroid (ICS) and never as monotherapy. Review concomitant asthma medication.
Monitor patients for cardiovascular adverse effects, especially those with pre-existing heart conditions.

Patient Guidelines

Use Vilatide daily as prescribed, even if you feel better. It is for maintenance treatment, not for sudden breathing problems.
Ensure you understand the correct technique for using the inhaler device. Incorrect use can lead to less effective medication delivery.
Do not exceed the prescribed dose. Using more than recommended may increase the risk of serious side effects.

Missed Dose Advice

If a dose is missed, skip the missed dose and take the next dose at the regularly scheduled time. Do not take two doses at one time or take extra doses.

Driving Precautions

Vilatide is not expected to affect the ability to drive or operate machinery. However, if you experience side effects like dizziness or tremor, exercise caution.

Lifestyle Advice

Avoid smoking and exposure to respiratory irritants, as these can worsen your condition.
Maintain a healthy lifestyle, including regular exercise (as advised by your doctor) and a balanced diet.